Capitalization 2.55B 2.77B 3.81B P/E ratio 2024 *
-10.5x
P/E ratio 2025 * -32.5x
Enterprise value 1.28B 1.39B 1.91B EV / Sales 2024 *
13.2x
EV / Sales 2025 * 7.55x
Free-Float
5.65%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.07%
Current month+0.22%
1 month+0.22%
6 months+106.05%
Current year+99.26%
More quotes
1 week
67.60
Extreme 67.6
67.85
1 month
67.30
Extreme 67.3
68.30
Current year
29.73
Extreme 29.73
69.75
1 year
14.52
Extreme 14.52
69.75
3 years
11.81
Extreme 11.805
69.75
5 years
11.81
Extreme 11.805
146.30
10 years
11.81
Extreme 11.805
146.30
More quotes
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 50 22-09-30
Investor Relations Contact - 06-08-31
Corporate Officer/Principal 59 17-12-31
Director TitleAgeSince
Director/Board Member 56 19-05-21
Director/Board Member - 06-05
Director/Board Member - 06-05
More insiders

Other Biotechnology & Medical Research

Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
0.00%0.00%+123.60%+23.90% 2.78B
-0.58%-2.29%-0.60%-64.95% 46.95B
-1.99%+3.14%+5.31%-3.53% 44.71B
+1.60%+1.40%+7.39%-26.11% 41.67B
+0.05%-5.73%+22.46%+29.11% 29.8B
-2.07%+0.26%+25.30%-25.53% 28.65B
-1.75%-3.54%+37.64%+53.19% 28.11B
+0.64%+1.93%+36.14%+81.25% 14.76B
-17.71%-21.76%+44.88%+96.45% 13.51B
-0.93%-3.27%-12.17%-34.90% 12.26B
Average -2.25%-0.05%+29.00%+12.89% 26.32B
Weighted average by Cap. -1.44%+0.43%+16.35%-1.99%
See all sector performances

Financials

Ratios2024 *2025 *
Net sales 190M 207M 285M 325M 353M 486M
Net income -243M -264M -363M -116M -126M -173M
Net Debt -30.15M -32.72M -45.05M -94.69M -103M -142M
More financial data * Estimated data
Logo MorphoSys AG
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Employees
464
Calendar
More about the company
Date Price Change Volume
24-07-23 67.75 0.00% 13 634
24-07-22 67.75 +0.15% 20,707
24-07-19 67.65 -0.07% 20,481
24-07-18 67.70 -0.07% 27,613
24-07-17 67.75 0.00% 18,531

Delayed Quote Xetra, July 23, 2024 at 11:36 am

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
67.75EUR
Average target price
58.71EUR
Spread / Average Target
-13.34%
Consensus